BFEC
GSK icon

Benjamin F. Edwards & Company’s GSK GSK Stock Holding History

Benjamin F. Edwards & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$156K Sell
4,042
-306
-7% -$12.9K ﹤0.01% 979
2024
Q1 		$187K Sell
4,348
-485
-10% -$20K ﹤0.01% 929
2023
Q4 		$179K Buy
4,833
+661
+16% +$23.7K ﹤0.01% 905
2023
Q3 		$151K Buy
4,172
+46
+1% +$1.63K 0.01% 802
2023
Q2 		$147K Sell
4,126
-233
-5% -$8.36K 0.01% 799
2023
Q1 		$155K Sell
4,359
-399
-8% -$14K 0.01% 783
2022
Q4 		$167K Buy
4,758
+208
+5% +$6.93K 0.01% 763
2022
Q3 		$134K Sell
4,550
-2,388
-34% -$90.5K 0.01% 788
2022
Q2 		$377K Sell
6,938
-951
-12% -$52.5K 0.02% 495
2022
Q1 		$430K Buy
7,889
+4,129
+110% +$224K 0.02% 490
2021
Q4 		$207K Sell
3,760
-38
-1% -$1.98K 0.01% 675
2021
Q3 		$181K Buy
3,798
+340
+10% +$17.1K 0.01% 688
2021
Q2 		$172K Sell
3,458
-228
-6% -$11K 0.01% 681
2021
Q1 		$164K Sell
3,686
-584
-14% -$26.5K 0.01% 722
2020
Q4 		$196K Buy
4,270
+796
+23% +$36.6K 0.01% 650
2020
Q3 		$163K Sell
3,474
-705
-17% -$35.3K 0.01% 638
2020
Q2 		$213K Sell
4,179
-416
-9% -$21.3K 0.02% 560
2020
Q1 		$218K Sell
4,595
-321
-7% -$17.1K 0.02% 495
2019
Q4 		$289K Buy
4,916
+468
+11% +$26K 0.02% 512
2019
Q3 		$237K Sell
4,448
-45
-1% -$2.31K 0.02% 524
2019
Q2 		$225K Sell
4,493
-1,005
-18% -$50.4K 0.02% 499
2019
Q1 		$287K Sell
5,498
-11,259
-67% -$563K 0.03% 442
2018
Q4 		$800K Buy
16,757
+2,038
+14% +$100K 0.08% 237
2018
Q3 		$739K Buy
14,719
+367
+3% +$18.6K 0.07% 268
2018
Q2 		$723K Sell
14,352
-3,774
-21% -$190K 0.07% 272
2018
Q1 		$885K Buy
18,126
+5,617
+45% +$262K 0.09% 234
2017
Q4 		$555K Sell
12,509
-6,871
-35% -$317K 0.06% 294
2017
Q3 		$984K Buy
19,380
+2,197
+13% +$111K 0.12% 175
2017
Q2 		$926K Buy
17,183
+477
+3% +$25.4K 0.12% 175
2017
Q1 		$880K Sell
16,706
-508
-3% -$25.8K 0.13% 174
2016
Q4 		$829K Buy
17,214
+936
+6% +$46.2K 0.14% 167
2016
Q3 		$878K Buy
16,278
+5,043
+45% +$277K 0.16% 145
2016
Q2 		$609K Sell
11,235
-1,047
-9% -$55.2K 0.12% 181
2016
Q1 		$623K Buy
12,282
+919
+8% +$45.8K 0.13% 166
2015
Q4 		$573K Sell
11,363
-95
-0.8% -$4.84K 0.12% 167
2015
Q3 		$551K Sell
11,458
-310
-3% -$16.1K 0.12% 170
2015
Q2 		$613K Buy
11,768
+2,400
+26% +$135K 0.12% 176
2015
Q1 		$540K Buy
9,368
+2,686
+40% +$154K 0.11% 181
2014
Q4 		$357K Buy
6,682
+2,004
+43% +$112K 0.08% 227
2014
Q3 		$269K Buy
4,678
+4,302
+1,144% +$264K 0.07% 271
2014
Q2 		$25K Hold
376
– – 0.01% 571
2014
Q1 		$25K Buy
376
+160
+74% +$10.8K 0.01% 539
2013
Q4 		$14K Sell
216
-324
-60% -$21K ﹤0.01% 600
2013
Q3 		$34K Buy
540
+2
+0.4% +$129 0.01% 443
2013
Q2 		$34K Buy
+538
New +$34.1K 0.01% 407

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

Benjamin F. Edwards & Company's GSK Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its GSK (GSK) stake by 7% in Q2 2024, selling an estimated $12.9K and leaving 4,042 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

Benjamin F. Edwards & Company first reported a position in GSK in Q2 2013 and has held it in 45 quarters since. The position peaked at $984K in Q3 2017. 885 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • Benjamin F. Edwards & Company held 4,042 shares of GSK worth $156K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 306 GSK shares in Q2 2024, an estimated $12.9K.
  • GSK made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #979 holding.
  • Benjamin F. Edwards & Company first reported a position in GSK in Q2 2013 and has held it in 45 quarters since.
  • Benjamin F. Edwards & Company's GSK position peaked at $984K in Q3 2017.
  • 885 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.